Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Estradiol Transdermal System Placebo - Alternate Adhesive
Estradiol System Placebo- Alternate Adhesive · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Estradiol Transdermal System Placebo - Alternate Adhesive |
| 2 | PLACEBO_COMPARATOR | Estradiol Transdermal System Placebo - Current Adhesive |
| Name | Type | Description |
|---|---|---|
| Estradiol Transdermal System Placebo - Alternate Adhesive | DRUG | single application |
| Estradiol Transdermal System Placebo - Current Adhesive | DRUG | single application |
Inclusion Criteria: 1. Age: 40-66 years. 2. Sex: Females only. 3. Weight: At least 52 kg (115 lbs) and within 20% of Ideal Body Weight (IBW), as referenced by the Table of ""Desirable Weights of Adults"" from Metropolitan Life Insurance Company, 1999 (See Part II: ADMINISTRATIVE ASPECTS OF HUMAN DE...
Estradiol System Placebo - Alternate Adhesive is a placebo transdermal patch developed by Viatris Inc. (ticker VTRS). It contains no active estradiol and is used as a comparator in a clinical study evaluating the adhesion quality and skin irritation of an alternate second generation estradiol transdermal system. It is a small molecule formulation.
Viatris Inc., which trades under the ticker VTRS, is the developer of Estradiol System Placebo - Alternate Adhesive. The company sponsored the clinical study of this placebo patch, which was conducted in the United States.
Estradiol System Placebo - Alternate Adhesive is in Phase 1 development. Its single Phase 1 trial has been completed, and no trials are currently active. The study was a randomized, placebo-controlled evaluation conducted in healthy female volunteers.
Estradiol System Placebo - Alternate Adhesive was evaluated in clinical trial NCT00650442, titled Evaluation of Adhesion Quality and Irritation of an Alternate Second Generation Estradiol Transdermal System. The Phase 1 trial enrolled 39 participants, was conducted in the United States, and has been completed.
Yes. Estradiol System Placebo - Alternate Adhesive is also known as Estradiol Transdermal System Placebo - Alternate Adhesive. Both names refer to the same placebo patch developed by Viatris Inc. for use as a comparator in the Phase 1 adhesion and irritation study.
The Phase 1 trial of Estradiol System Placebo - Alternate Adhesive enrolled 39 healthy female volunteers aged 40 years and older in the United States. The study was randomized and placebo-controlled, and it assessed adhesion quality and skin irritation of an alternate second generation estradiol transdermal system.